Boehringer Ingelheim has announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in several European countries. Spiolto Respimat® is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

The drug has been approved in Croatia, United Kingdom, Slovakia, Denmark, Norway, Ireland, Austria, Romania, and Spain. Approvals of the treatment in other European countries are expected to follow in the coming months.

Spiolto Respimat®is built on tiotropium, the active ingredient in Boehringer Ingelheim’s Spiriva, a treatment for COPD, and is enhanced by olodaterol, a long-acting beta2-agonist with a fast onset of action, specifically designed to complement the efficacy of Spiriva. Spiolto is delivered by Respimat, an inhaler that delivers a mist, meaning the patient needs to breathe in naturally for the medication to go deep into the lungs.

Source: Boehringer Ingelheim